Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Preps Eritoran For Phase III Sepsis Trial Based On Phase II Mortality Reduction

This article was originally published in The Pink Sheet Daily

Executive Summary

Closest competitor appears to be Takeda, which plans Phase III study this summer for its own TLR4 inhibitor for severe sepsis.

You may also be interested in...



AstraZeneca Licenses Protherics Sepsis Treatment

AstraZeneca will take the polyclonal antibody fragment CytoFab into Phase III trials in 2007, following a manufacturing upgrade.

AstraZeneca Licenses Protherics Sepsis Treatment

AstraZeneca will take the polyclonal antibody fragment CytoFab into Phase III trials in 2007, following a manufacturing upgrade.

Xigris "Dear Doctor" Letter Follows Termination Of Pediatric Sepsis Trial

Lilly says a data monitoring committee determined that Xigris was "highly unlikely to show improvement over placebo" in the study's primary endpoint – composite time to complete organ failure resolution.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel